Market Access

Latest News


Drugs for Obesity Treatment (Adobe Stock 98397783): © jarun011 - stock.adobe.com

George Hampton, president and CEO, Currax Pharmaceuticals, discusses the obesity treatment landscape, payment options available to insured and uninsured patients, and how pharma can make obesity treatments more affordable in an exclusive Q&A with Pharm Exec.

In this exclusive Q&A, Vishali Amin, chief of staff to the office of the president and senior director of customer success for Kalderos, discusses the biggest hurdles to drug affordability, how patients can become aware of drug discounts, how drugs are selected for regulatory discount programs, and drug pricing strategies.

In this exclusive Q&A, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, shares her perspective on the biggest drug pricing challenges today, current efforts to lower drug pricing, and the Inflation Reduction Act.

Doron Aspitz

Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.

Stefan Merlo, Vice President, Commercial Development at CSL Seqirus | Image from video.

Stefan Merlo, Vice President, Commercial Development, CSL Seqirus discusses how COVID-19 has evolved the discussion of vaccines and the long-term concerns stemming from flu vaccine fatigue.